Learn more

SHANGHAI INST MATERIA MEDICA CAS

Overview
  • Total Patents
    790
  • GoodIP Patent Rank
    2,002
  • Filing trend
    ⇩ 15.0%
About

SHANGHAI INST MATERIA MEDICA CAS has a total of 790 patent applications. It decreased the IP activity by 15.0%. Its first patent ever was published in 2007. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are THERAVANCE BIOPHARMA R&D IP LLC, JANSSEN R & D IRELAND and SOPHARMA SA.

Patent filings per year

Chart showing SHANGHAI INST MATERIA MEDICA CASs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Jiang Hualiang 182
#2 Ding Jian 159
#3 Chen Kaixian 132
#4 Geng Meiyu 121
#5 Liu Hong 118
#6 Li Jia 101
#7 Ai Jing 67
#8 Li Jian 65
#9 Wang Jiang 63
#10 Chen Yi 57

Latest patents

Publication Filing date Title
WO2021078150A1 Pentacyclic triterpene tgr5 receptor agonist and preparation method therefor and uses thereof
WO2021063366A1 Drug for treating artery-related diseases, and use thereof
WO2021052501A1 Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
WO2021047677A1 Irak4 kinase inhibitor and preparation thereof and use thereof
WO2021047464A1 Use of 4-[9-(6-aminopurinyl)]-2(s)-hydroxymethyl butyrate for preparing ophthalmic preparations
WO2021043217A1 Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof
WO2021037188A1 Pharmaceutical use of pyrimido[5,4-b]pyrrolizine compound
WO2021037244A1 Pharmaceutical composition and application thereof
WO2021037160A1 Tumor enzyme-responsive recombinant pyroptosis protein delivery system and antitumor use thereof
WO2021036937A1 Application of pde3 inhibitor and cytokine in treatment of tumor
CN111728953A Sustained-release preparation of tofacitinib or salt thereof and preparation method thereof
CN112239459A Fused ring pyrimidine amino compound, preparation method thereof, pharmaceutical composition and application
CN111920541A Method for constructing sepsis compound animal model
WO2020259612A1 Antidepressant steroid compound
WO2020259539A1 4-pyridine substituted phthalazinone compound and preparation method, pharmaceutical composition, and use thereof
CN112094266A Pyrrolopyridinone compound, preparation method, composition and application thereof
CN111892648A Novel coronavirus polypeptide vaccine coupled with TLR7 agonist and application thereof
WO2020244518A1 Compound with benzyloxy aromatic ring structure, preparation method and use thereof
CN112010859A Fused ring compound, preparation method and application thereof
CN111574441A Eutectic of nicorandil and salicylic acid as well as preparation method and application of eutectic